Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
      QxMD      Google Scholar   
Citation:
Blood Adv vol 2 (24) 3608-17
Year:
2018
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
8
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Takeda  
Grants:
U10CA180821, U10CA180882, U10CA180836, U10CA180850, U10CA180866, U10CA180867, P30CA033572  
Corr. Author:
 
Authors:
                                           
Networks:
CA043, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NY158, LAPS-OH007, NC002, NORTHWELL, NY018   
Study
CALGB-11002
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: